Influence of the Common Human δ-Aminolevulinate Dehydratase Polymorphism on Lead Body Burden

James G. Wetmur

Department of Microbiology, Mount Sinai School of Medicine, New York, New York

δ-Aminolevulinate dehydratase (ALAD) is the second enzyme in the heme biosynthesis pathway. ALAD is a zinc metalloenzyme, and its inhibition by lead substitution for zinc is one of the most sensitive indicators of blood-lead accumulation, a measure of recent lead exposure. Stoichiometry calculations indicate that a significant portion of blood lead is stored in ALAD. Human ALAD exhibits a charge polymorphism, with about 20% of Caucasians expressing the rarer ALAD^δ allele. Human ALAD^δ and ALAD^δ cDNAs and the 16-kb ALAD gene have been cloned and sequenced. A simple polymerase chain reaction test has been established and validated for determining ALAD genotypes. Two population studies have indicated that lead-exposed individuals with the ALAD^δ allele have blood-lead levels about 10 μg/dl greater than similarly exposed individuals carrying only the ALAD^γ allele. Ongoing work is directed toward determining the biochemical underpinning of the allele-specific accumulation of blood lead, and toward determining the contribution of human ALAD genotype to lead accumulation in other tissues in transgenic mouse models and to final lead deposition in bone in both mouse and man. — Environ Health Perspect 102(Suppl 3):215–219 (1994)

Key words: lead, δ-aminolevulinate dehydratase, polymorphism, blood, human, zinc, metalloenzymes

Introduction

Exposure to environmental lead may affect numerous organ systems, including the renal, reticuloendothelial, reproductive, and nervous systems. Of particular importance, exposure to low levels of lead in utero or in early childhood may lead to irreversible central nervous system damage (1–8). Although the reduced use of leaded gasoline, widespread detection of lead-based paint poisoning of children, and control of lead exposure in the workplace have combined to substantially reduce the incidence of acute lead poisoning in the United States, exposure to low doses of lead is still quite common. The Second National Health and Nutrition Examination Survey (NHANES-II) found that 1.5 million preschool children had blood lead levels of 25 μg/dl and above, indicating significant lead absorption.

The homooctameric zinc metalloenzyme, δ-aminolevulinate dehydratase (porphobilinogen synthase, ALAD, EC 4.2.1.24), is the second enzyme in the heme biosynthetic pathway. ALAD is expressed in all tissues, but occurs at elevated levels in liver, which has the added burden of cytochrome P450 synthesis, and in the highest levels in erythrocytes and their precursors. ALAD is stoichiometrically inhibited by lead (9–11), with lead replacing zinc. Erythrocyte ALAD inhibition has been used as a routine lead-poisoning test in many clinical chemistry laboratories.

Lead inactivation of ALAD has been implicated in the pathogenesis of lead poisoning (12,13). The substrate of ALAD, δ-aminolevulinate (ALA), which accumulates in lead poisoning, has been shown to be capable of acting as a neuropathogenic agent (11,11–14). In fact, the clinical features of acute lead poisoning closely resemble those of the acute attacks in acute intermittent porphyria (AIP), during which ALA accumulates. AIP is a dominant porphyria due to half-normal levels of the third enzyme in the heme biosynthesis pathway. Furthermore, affected individuals with the recessive ALAD-deficient porphyria manifest chronic neurologic manifestations (20–22). Finally, asymptomatic heterozygotes for the latter porphyria develop acute lead poisoning when exposed to low levels of lead (23,24).

Three distinct charge isozymes, designated ALAD^1–1, 1–2, and 2–2 (25,26), result from the expression of two common alleles, designated ALAD^1 and ALAD^2, with gene frequencies of 0.9 and 0.1, respectively, in several Caucasian populations (25–28). The existence of this frequent polymorphism in a gene whose product was implicated in the pathogenesis of lead toxicity suggested the potential for a genetically determined differential susceptibility. We determined the ALAD isozyme types of 1278 blood samples from children subjected to low-level environmental lead exposure in New York City (28,29). The blood lead level, measured by the New York City Lead Screening Program, and the ALAD isozyme phenotype were determined in a double-blind fashion. Blood lead levels and isozyme phenotypes were also determined for a population of 202 lead workers in a factory in Germany (30). Analysis of both populations (29) revealed that individuals carrying the ALAD^2 allele were at significantly greater risk of lead poisoning (p<0.0001 and p<0.004, respectively), with individuals carrying the ALAD^2 allele having about 10 μg/dl higher levels of blood lead than similarly exposed individuals who were homozygous for ALAD^1 allele. Human ALAD^1 and ALAD^2 cDNAs have been cloned and sequenced in our laboratory (31,32), and a simple polymerase chain reaction (PCR) test, based on different cleavage patterns of the two alleles by MspI, has been developed for genotyping ALAD alleles in individuals who were exposed to lead. The present status of human studies of the contribution of ALAD genotype to lead poisoning is detailed below in the Results and Discussion section. Of special interest will be not only the acute measure of erythrocyte lead but
also the chronic measures of dentine or bone lead.

The results reported above are consistent with the testable hypothesis that the ALAD\(^1\) subunit binds lead more effectively, with similarly exposed ALAD\(^2\) heterozygotes and homozygotes having higher blood lead concentrations and possibly higher lead body burden than ALAD\(^1\) homozygotes. We have developed an expression system that allows production of large quantities of human ALAD 1–1 and ALAD 2–2 in Escherichia coli (Kaya AH and Desnick RJ, unpublished results). The present status of biochemical studies of the contribution of these ALAD isozymes to lead poisoning is detailed in the Results and Discussion section. Of particular interest will be the competition between lead and zinc for binding to the isozymes.

The human genomic sequence containing ALAD has been determined (15,913 bp, accession number X64467) in both orientations (33). The gene encodes 13 exons: 11 coding exons—exons 2 to 12—and 2 alternative noncoding exons—1A and 1B. The promoter with exon 1A was found to function in all cells, while the promoter of exon 1B functions exclusively in erythroid cells. The Results and Discussion section proposes mouse model experiments of lead tissue distribution, based either on published data showing variation in murine ALAD gene dose in various mouse strains (34) or on production of transgenic mice carrying either ALAD\(^1\) or ALAD\(^2\) human minigenes with promoters for either exon 1A or 1B. Of special interest will be the acute measure of erythrocyte lead, the chronic measure of bone lead, and the pathophysiologically important distribution of lead into brain.

**Materials and Methods**

**Human Studies**

*Populations.* To date only two populations have been studied (double-blind) for blood lead and ALAD phenotype (29). One group consisted of 202 male workers who were exposed to different amounts of lead for different periods of time in a German factory. The other group consisted of 1278 children from lower socioeconomic neighborhoods in New York City; at least 27 and 20% were Black and Hispanic, respectively. They had initially been screened for possible lead poisoning by the New York City Department of Health and found to have elevated free erythrocyte protoporphyrin (FEP) levels.

Additional collaborations have been established to study ALAD genotypes by PCR and MspI cleavage analysis in populations in which a chronic measure of lead exposure is available. H Hu, D Bellinger (Harvard), H Needham (Pittsburgh): chronic measure, dentine of deciduous teeth. B Fowler, E Silbergeld (University of Maryland): acute measure, blood lead; chronic measure, bone lead. DR Chettle (McMaster), L Gerhardsson, S Skerfving (Lund), V Englström (Boliden Metall AB): acute measure, blood lead history; chronic measure, bone lead. A Todd and P Landrigan (Mount Sinai, New York): acute measure, blood lead; chronic measure, bone lead.

**PCR** ALAD genotyping by PCR is carried out as previously described (32).

**ALAD 1-1 and ALAD 2-2 Biochemistry**

*Expression Vectors.* ALAD\(^1\) and ALAD\(^2\) cDNAs were ligated into a pUC19 vector with a linker such that the inducible-galactosidase promoter encoded a coisotropic message encoding a short polypeptide followed by the complete human ALAD polypeptide (35). The construct contained the sequence AAGCTTGAGGAATTTCAAGCCATG from the pUC19 HindIII (AAGCTT) site to the ALAD initiation codon (ATG), with TAA being the terminator for the short polypeptide and AGGAA being a ribosome binding site. The vectors were cloned into E. coli LC137, a lon- and htp-g strain, and the inserts were completely sequenced.

**Recombinant Human ALAD 1-1 and ALAD 2-2 Isozymes.** Authentic, soluble, and biologically active human ALAD 1–1 and ALAD 2–2 were synthesized. The ALAD enzymatic activity was 0.7 U/mg protein, over 1000 times that found in human erythrocytes (0.45 mU/mg protein). The recombinant protein was identical to human erythrocyte protein by sedimentation velocity, polyacrylamide gel electrophoresis mobility, and Western blotting (Kaya AH and Desnick RJ, unpublished results). Purification of ALAD 1–1 and ALAD 2–2 follows the method of Anderson and Desnick (36).

**Animal Model Studies**

The 15,913 base pairs of human genomic sequence containing ALAD\(^1\) were determined in both orientations (HSALADG, accession number X64467 (33)). The analysis of the genome structure of human ALAD, necessary for constructing transgenic mice expressing human ALAD, is illustrated in Figure 1.

**Results and Discussion**

**Human Studies**

The results of the two completed studies demonstrating a relationship between blood lead levels and ALAD phenotype (29) are summarized in Table 1. In the 40 to 60 percentile group for blood lead in each phenotype group, individuals with the ALAD\(^2\) allele (phenotypes ALAD 1–2 and ALAD 2–2) have of the order of 10 µg/dl greater blood lead than similarly exposed individuals homozygous for the ALAD\(^1\) allele (phenotype ALAD 1–1). The German lead workers (FRG) showed the expected ALAD\(^2\) gene frequency of about 0.1 for a Caucasian population. The children from New York City showed an ALAD\(^2\) allele frequency of 0.06, consistent with inclusion of approximately 30% of children of African ancestry. No ALAD\(^2\) alleles were detected in one African population (27). The results were not changed in a reanalysis excluding these children.

**Table 1. Summary of statistics on the correlation of ALAD phenotype and blood lead.**

| Population | Phenotype | Blood lead, µg/dl | Blood lead, µg/dl |
|------------|-----------|-------------------|-------------------|
|            | ALAD 1–1  | ALAD 2–2         |                   |
| USA        |           |                   |                   |
| Number analyzed | 1136       | 142               |                   |
| 40         | 12        | 20                |                   |
| 50         | 15        | 26                |                   |
| 60         | 18        | 32                |                   |
| Mean ± SEM | 19.5 ± 0.3 | 27.1 ± 1.3        |                   |
| FRG        |           |                   |                   |
| Number analyzed | 160       | 42                |                   |
| 40         | 31        | 41                |                   |
| 50         | 35        | 44                |                   |
| 60         | 40        | 53                |                   |
| Mean ± SEM | 36.4 ± 1.3 | 47.9 ± 2.8        |                   |
The FRG population was unselected, consisting of all participating lead workers at a factory site. The USA population consisted of children whose FEP levels on initial screening suggested the possibility of lead poisoning. FEP levels are known to be affected by other variables, including iron status (36). Although the identical dependence of blood lead level on ALAD isozyme phenotype for both populations argues against any bias introduced by the FEP prescreening of the USA population, additional population studies of ALAD genotype (and hence phenotype) and blood lead are needed to prove the ALAD to be a lead susceptibility allele. Blood lead and ALAD genotype studies are in planning or in progress in populations 1 to 4 (Materials and Methods), and we welcome additional collaborative arrangements.

Blood lead is an acute measure of lead exposure. For example, there was insignificant correlation between time on the job and blood-lead level in the FRG population. If we accept the hypothesis that the ALAD 2 polypeptide binds lead tighter than the ALAD 1 polypeptide, the effect of this enhanced binding of lead on the eventual tissue distribution of lead cannot be predicted. In one scenario, ALAD 2, which is present at much higher concentrations in blood than in other tissues, could compete with lead binding proteins in brain or other organs and reduce pathology. On the other hand, increased inhibition of heme synthesis in tissues with low levels of ALAD could increase pathology. An important contribution to understanding the lead distribution problem would be to correlate instantaneous blood lead levels and lead body burden.

Integrated measures of lead exposure include lead in dentine of deciduous teeth of children and bone lead in both children and adults. Measurements of ALAD genotype together with integrated measures of lead exposure are in planning or in progress in populations 1 to 4 (Materials and Methods). The populations are listed in increasing order of numbers of subjects. Because of the low frequency of ALAD even in Caucasian populations, the populations of lead-exposed individuals on whom integrated measures are performed must be quite large to lead to highly informative data; not even the largest of the populations identified to date is ideal. Once again, we invite collaborative arrangements.

ALAD 1-1 and ALAD 2-2 Biochemistry

The argument that erythrocyte ALAD binds a substantial fraction of the blood lead is outlined in Table 2. A unit (U) of ALAD is defined as the quantity of enzyme producing 1 nmole porphobilinogen (PBG) per hour at 37°C. The calculation includes the ALAD activity in human erythrocyte lysate (38) of approximately 4.7 U/mg protein (mostly hemoglobin) and the turnover number of 11 mole/min/mole ALAD subunit (36). The conclusion is that at least 10 µg/dl lead is bound to ALAD at 25 µg/dl total blood lead. This minimum estimate is based on ALAD enzymatic activity, which decreases throughout the 120-day life-span of erythrocytes. Additional lead could be bound to inactive ALAD.

Thus the difference in observed blood lead values for individuals with different ALAD phenotype could be explained by the hypothesis that ALAD 2 subunits bind lead more avidly than ALAD 1 subunits.

Further support for this hypothesis could be obtained by comparison of the lead binding properties of the purified ALAD 1–1 and 2–2 proteins. To accomplish this objective, milligram quantities of the isozymes ALAD 1–1 and ALAD 2–2 would be needed, and the only practical source would be recombinant enzymes. Previous studies of the activities of the erythrocyte ALAD 1–1 or ALAD 2–2 isozymes have failed to detect a difference [(25,30), Ostasiwicz and Desnick, unpublished results], but these studies were carried out either with unpurified or with limited quantities of purified ALAD 2–2 isozyme.

Animal Model Studies

To understand the physiologic consequences of the increased blood lead observed in individuals with the ALAD allele, we must understand the effect of ALAD isozyme phenotype on the distribution of lead to other organs, including kidney, where specific metal-binding proteins mediate the effect of lead on ALAD, bone—the ultimate repository of much of the lead—and especially brain. Mice are especially sensitive to the effects of lead, and lead binding in various organ systems is readily determined. Furthermore, uninhibited erythrocyte ALAD activity is proportional to gene dose in commercially available mouse strains carrying one (C57BL/6), two (C58), or three (DBA/2) copies of the murine ALAD gene per haploid genome (33). Thus we are investigating these mice to establish the effect of ALAD concentration, especially in serum, on the pharmacokinetics of lead tissue distribution. These studies will be the basis for measurement and analysis in the more important animal model system based on expression of human ALAD alleles in transgenic mice.

Table 2. Lead binding to erythrocyte ALAD and blood lead.

| ALAD | Erythrocyte ALAD activity = 4.7 nmole PBG/hr/mg lysate protein (38) |
|------|-------------------------------------------------------------------|
| Erythrocyte ALAD activity = 12 nmole PBG/min/mg whole blood |
| Turnover number = 11 nmole PBG/min/mole ALAD subunit (35) |
| ALAD Subunits ≥ 1 nmole/mI whole blood |
| Lead | 1 nmole/mI = 21 µg Pb/dl |
| ALAD inhibition by lead |
| Inhibition is without threshold |
| Approximately 50% inhibited at 25 µg Pb/dl |
| Conclusion |
| >10 µg Pb/dl bound to ALAD at 25 µg/dl blood lead |

Figure 1. ALAD gene structure. Numbered exons are shown as large blocks. Promoter regions for noncoding exons 1A and 1B are indicated.
As described in Materials and Methods, our efforts to date have been directed toward analysis of the human ALAD gene with particular emphasis on the promoter regions. The structure of the human ALAD gene is shown in Figure 1. Expression analysis of the two promoters reveals that in both cases a DNA sequence of less than 400 base pairs produces as much product as longer constructs and exhibits tissue specificity. Thus, four minigenes are being constructed containing either exons 2 to 12 of ALAD\(^1\) or ALAD\(^2\) and either exon 1A or exon 1B with their corresponding promoters. We propose to construct transgenic mice expressing similar numbers of copies of either the human ALAD\(^1\) or ALAD\(^2\) allele. The analysis of lead-exposed animals will be directed toward the study of the acute measure of erythrocyte lead, the chronic measure of bone lead, and the pathophysiologically important distribution of lead into brain. In summary, we are taking advantage of the tools of molecular biology to study the ecogenetics of lead poisoning. Our integrated tripartite approach is to study ALAD allele frequency in lead-exposed individuals by PCR, ALAD isozyme biochemistry with recombinant proteins, and the effect of human ALAD alleles on lead pharmacokinetics in transgenic mice.

REFERENCES

1. Needleman HL, Gunnoc E, Levitom A, Reed R, Peresin H, Maher C, Barrett P. Deficits in psychologic and classroom performance of children with elevated dentine lead levels. N Engl J Med 300:689–695 (1979).
2. Winneke G, Kramer U, Brockhaus A, Ewers U, Kujanek G, Lechner H, Janke W. Neuropsychological studies in children with elevated tooth-lead concentrations. I. Extended study. Int Arch Occup Environ Health 51:231–252 (1983).
3. Bellinger D, Chisolm JR, Wasserman M, Needleman H, Rabinowitz M. Longitudinal analysis of prenatal and postnatal lead exposure in early cognitive development. N Engl J Med 316:1037–1043 (1987).
4. McMichael AJ, Baghurst PA, Wigg NR, Vimpani GV, Robertson EF, Roberts RJ. Port Pirie cohort study: environmental exposure to lead and children’s abilities at the age of four years. N Engl J Med 319:468–475 (1988).
5. Bergomi M, Borella P, Fantuzzi G, Vivoli G, Sturloni N, Cavazzuti G, Tampieri A, Tartoni, PL. Relationship between lead exposure indicators and neuropsychological performance in children. Dev Med Child Neurol 31:181–190 (1989).
6. Needleman HL, Schell A, Bellinger D, Leviton A, Allred EN. The long-term effects of exposure to low doses of lead in childhood. N Engl J Med 322:83–88 (1990).
7. Winneke G, Brockhaus A, Ewers U, Kramer U, Neuf M. Results from the European multicenter study on lead neurotoxicity in children: implications for risk assessment. Neurotoxicol Teratol 12:553–559 (1990).
8. Lippmann M. Lead and human health: background and recent findings. Environ Res 51:1–24 (1991).
9. Chisolm JJ Jr, Thomas DJ, Hamill TC. Erythrocyte porphobilinogen synthase activity as an indicator of lead exposure in children. Clin Chem 31:601–605 (1985).
10. Rogn WJ, Reighart JR, Gladen BC. Association of aminolevulinate dehydratase levels and ferrochelatase inhibition in childhood lead exposure. J Pediatr 109:60–64 (1986).
11. Jaffe EK, Baglia S, Michini PA. Reevaluation of a sensitive indicator of early lead exposure. Measurement of porphobilinogen synthase in blood. Biol Trace Element Res 28:223–231 (1991).
12. Bottomley SS, Muller-Eberhard U. Pathophysiology of heme synthesis. Semin Hematol 25:282–302 (1988).
13. Kappas A, Sasa S, Galbraith RA, Nordmann Y. The porphyrins. In: The Metabolic Basis of Inherited Disease, 6th ed (Scriver CR, Beaudet AL, Sly WS, Valle D, eds). New York:McGraw-Hill, 1989;1305–1365.
14. Muller WE, Snyder SH. \(\delta\)-Aminolevulinic acid: influences on synaptic GABA receptor binding may explain CNS symptoms of porphyria. Ann Neurol 3:240–342 (1977).
15. Brennan MJ, Cantrill RC. Delta-aminolevulinic acid is a potent agonist for GABA autoreceptors. Nature 380:514–515 (1979).
16. Brennan MJ, Cantrill RC. Delta-aminolevulinic acid and amino acid neurotransmitters. Mol Cell Biochem 38:49–58 (1981).
17. Audeisik G. Effects of lead exposure on the physiology of neurons. Prog Neurobiol 24:199–231 (1985).
18. Cutler MG, McLaughlin M, McNeil E, Moore MR. Effects of delta-aminolevulinic acid on contractile activity in the isolated small intestine of the rabbit. Neuropharmacol 24:1005–1009 (1985).
19. Minnema DJ, Michaelson IA. Differential effects of inorganic lead and delta-aminolevulinic acid in vitro on synaptosomal gamma-aminobutyric acid release. Toxicol Appl Pharmacol 86:437–447 (1986).
20. Doss M, von Tiepermann R, Schneider J, Schmid H. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr 68:1123–1127 (1979).
21. Thunell S, Holmberg L, Lundgren J. Aminolevulinic dehydratase porphyria in infancy. A clinical and biochemical study. Clin Chim Clin Biochem 25:5–14 (1987).
22. Hassoun A, Verstraeten L, Mercels R, Martin J-J. Biochemical diagnosis of an hereditary aminolevulinate dehydratase deficiency in a 63-year-old man. J Clin Chim Clin Biochem 27:781–786 (1989).
23. Doss M, Laubenthal F, Stoeppler M. Lead poisoning in inherited \(\delta\)-aminolevulinic acid dehydratase deficiency. Int Arch Occup Environ Health 54:55–63 (1984).
24. Doss M, Muller WA. Acute lead poisoning in inherited porphobilinogen synthase (\(\delta\)-aminolevulinic acid dehydratase) deficiency. Blu 45:131–139 (1982).
25. Battistuzzi G, Petrucci R, Silvagni L, Urbani FR, Caiola S. \(\delta\)-aminolevulinate dehydratase: a new genetic polymorphism in man. Ann Hum Genet 45:223–229 (1981).
26. Petrucci R, Leonard A, Battistuzzi G. The genetic polymorphism of human \(\delta\)-aminolevulinate dehydratase in Italy. Hum Genet 60:289–290 (1982).
27. Benkman H-G, Bogdanski P, Goedde HW. Polymorphism of delta-aminolevulinic acid dehydratase in various populations. Hum Genet 33:62–64 (1983).
28. Astrin KH, Bishop DF, Wetmur JG, Kaul B, Davidow B, Desnick RJ. \(\delta\)-aminolevulinic acid dehydratase isozymes and lead toxicity. In: Mechanisms of Chemically-Induced Porphyropathies, Vol 514 (Silbergeld EK, Fowler BA, eds). New York:Ann N Y Acad Sci, 1987;23–29.
29. Wetmur JG, Lehnert G, Desnick RJ. The \(\delta\)-aminolevulinate dehydratase polymorphism: higher blood lead levels in lead workers and environmentally-exposed children with the 1–2 and 2–2 isozymes. Environ Res 56:105–119 (1991).
30. Zemmenn B, Angerer J, Lehnert G, Benkman H-G, Goedde HW. Polymorphism of delta-aminolevulinic acid dehydratase in lead-exposed workers. Int Arch Occup Environ Health 58:245–247 (1986).
31. Wetmur JG, Bishop DF, Cantelmo C, Desnick RJ. Human \(\delta\)-aminolevulinate dehydratase: nucleotide sequence of a full-length cDNA clone. Proc Natl Acad Sci USA 83:7703–7707 (1986).
32. Wetmur JG, Kaya AH, Plewinska M, Desnick RJ. Molecular characterization of the human \(\delta\)-aminolevulinate dehydratase \(^*\) (ALAD\(^*\)) allele: implications for molecular screening of individuals for genetic susceptibility to lead poisoning. Am J Hum Genet 49:167–174 (1991).
33. Kaya AH, Plewinska M, Wong DM, Desnick RJ, Wetmur JG. Human \(\delta\)-aminolevulinate dehydratase gene: structure and alternative splicing of the erythroid and housekeeping mRNAs. Genomics 19:242–248 (1994).
34. Bishop TR, Cohen PJ, Boyer SH, Noyes AN, Frelin LP. Isolation of a rat liver δ-aminolevulinate dehydratase (ALAD) cDNA clone: evidence for unequal ALAD gene dosage among inbred mouse strains. Proc Natl Acad Sci USA 83:5568-5572 (1986).
35. Kaya AH. Molecular genetic studies of human delta-aminolevulinic dehydratase. PhD thesis, Mount Sinai School of Medicine (1992).
36. Anderson PM, Desnick RJ. Purification and properties of δ-aminolevulinate dehydratase from human erythrocytes. J Biol Chem 254:6924-6930 (1979).
37. Marcus AH, Schwartz J. Dose–response curves for erythrocyte protoporphyrin vs blood lead: effects of iron status. Environ Res 44:221-227 (1987).
38. Giampietro PF, Desnick RJ. Determination of δ-aminolevulinate dehydratase activity by a specific fluorometric coupled-enzyme assay. Anal Biochem 131:83–92 (1983).